Hepatitis B virus (HBV) iRNA compositions and methods of use thereof
The present invention relates to RNAi agents, e.g., double-stranded RNAi agents, targeting the hepatitis B virus (HBV) genome, and methods of using such RNAi agents to inhibit expression of one or more HBV genes and methods of treating subjects having an HBV infection and/or HBV-associated disorder, e.g., chronic hepatitis B infection.
1. A double stranded RNAi agent for inhibiting expression of hepatitis B virus (HBV) in a cell, wherein said double stranded RNAi agent comprises a sense strand and an antisense strand forming a double-stranded region,
wherein the sense strand comprises 5′-GGUGGACUUCUCUCAAUUUUA-3′ (SEQ ID NO:11), and the antisense strand comprises 5′-UAAAAUUGAGAGAAGUCCACCAC-3′ (SEQ ID NO:12),
wherein substantially all of the nucleotides of said sense strand and substantially all of the nucleotides of said antisense strand are modified nucleotides,
wherein said sense strand is conjugated to a ligand attached at the 3′-terminus, and
wherein the ligand is one or more GalNAc derivatives and it is attached to the 3′ terminus of said sense strand through a bivalent or trivalent branched linker.
2. The double stranded RNAi agent of claim 1 , wherein all of the nucleotides of said sense strand and all of the nucleotides of said antisense strand are modified nucleotides.
3. The double stranded RNAi agent of claim 1 , wherein at least one of said modified nucleotides is selected from the group consisting of a deoxy-nucleotide, a 3′-terminal deoxy-thymine (dT) nucleotide, a 2′-O-methyl modified nucleotide, a 2′-fluoro modified nucleotide, a 2′-deoxy-modified nucleotide, a locked nucleotide, an unlocked nucleotide, a conformationally restricted nucleotide, a constrained ethyl nucleotide, an abasic nucleotide, a 2′-amino-modified nucleotide, a 2′-O-allyl-modified nucleotide, 2′-C-alkyl-modified nucleotide, 2′-hydroxyl-modified nucleotide, a 2′-methoxyethyl modified nucleotide, a 2′-O-alkyl-modified nucleotide, a morpholino nucleotide, a phosphoramidate, a non-natural base comprising nucleotide, a tetrahydropyran modified nucleotide, a 1,5-anhydrohexitol modified nucleotide, a cyclohexenyl modified nucleotide, a nucleotide comprising a phosphorothioate group, a nucleotide comprising a methylphosphonate group, a nucleotide comprising a 5′-phosphate, and a nucleotide comprising a 5′-phosphate mimic.
4. The double stranded RNAi agent of claim 1 , wherein at least one strand comprises a 3′ overhang of at least 1 nucleotide; or at least one strand comprises a 3′ overhang of at least 2 nucleotides.
5. The double stranded RNAi agent of claim 1 , wherein the double-stranded region is 21-30 base pairs in length.
6. The double stranded RNAi agent of claim 1 , wherein the ligand is
7. The double stranded RNAi agent of claim 1 , wherein the ligand attached through a bivalent or trivalent branched linker is
wherein X is O or S.
8. The double stranded RNAi agent of claim 1 , wherein at least one of said modified nucleotides is a 2′-O-methyl modified nucleotide, a 2′-fluoro modified nucleotide, or a nucleotide comprising a phosphorothioate group.
9. The double stranded RNAi agent of claim 1 , wherein the sense strand comprises the nucleotide sequence of 5′-gsgsuggaCfuUfCfUfcucaAfUfuuua-3′ (SEQ ID NO:25) and the antisense strand comprises the nucleotide sequence of 5′-usAfsaaaUfuGfAfgagaAfgUfccaccsasc-3′ (SEQ ID NO:26),
wherein a, g, c, and u are 2′-O-methyl (2′-OMe) A, 2′-OMe G, 2′-OMe C, and 2′-OMe U, respectively; Af, Cf, Gf, and Uf are 2′-fluoro A, 2′-fluoro C, 2′-fluoro G, and 2′-fluoro U, respectively; and s is a phosphorothioate linkage.
10. The double stranded RNAi agent of claim 9 , wherein the ligand is
11. The double stranded RNAi agent of claim 9 , wherein the ligand attached through a bivalent or trivalent branched linker is
wherein X is O or S.
12. A pharmaceutical composition comprising the double stranded RNAi agent of claim 1 and a pharmaceutically acceptable carrier.
13. A pharmaceutical composition comprising the double stranded RNAi agent of claim 9 and a pharmaceutically acceptable carrier.
14. A pharmaceutical composition comprising the double stranded RNAi agent of claim 11 and a pharmaceutically acceptable carrier.
15. A pharmaceutical composition for inhibiting expression of hepatitis B virus (HBV) in a cell, comprising:
(a) the double stranded RNAi agent of claim 1 ; and
(b) a second double-stranded RNAi agent comprising a second sense strand and a second antisense strand forming a second double-stranded region,
wherein the second sense strand comprises 5′-GUGUGCACUUCGCUUCACA-3′ (SEQ ID NO:39), and the second antisense strand comprises 5′-UGUGAAGCGAAGUGCACACUU-3′ (SEQ ID NO:40),
wherein substantially all of the nucleotides of the second sense strand and substantially all of the nucleotides of the second antisense strand are modified nucleotides,
wherein the second sense strand is conjugated to a ligand attached at the 3′-terminus, and
wherein the ligand is one or more GalNAc derivatives attached through a bivalent or trivalent branched linker; and
(c) a pharmaceutically acceptable carrier.
16. The pharmaceutical composition of claim 15 , wherein
(a) the first sense strand comprises 5′-gsgsuggaCfuUfCfUfcucaAfUfuuua-3′ (SEQ ID NO:25) and the first antisense strand comprises 5′-usAfsaaaUfuGfAfgagaAfgUfccaccsasc-3′ (SEQ ID NO:26); and
(b) the second sense strand comprises 5′-gsusguGfcAfCfUfucgcuucaca-3′ (SEQ ID NO:41) and the second antisense strand comprises 5′-usGfsugaAfgCfGfaaguGfcAfcacsusu-3′ (SEQ ID NO:42);
wherein a, g, c, and u are 2′-O-methyl (2′-OMe) A, 2′-OMe G, 2′-OMe C, and 2′-OMe U, respectively; Af, Cf, Gf, and Uf are 2′-fluoro A, 2′-fluoro C, 2′-fluoro G, and 2′-fluoro U, respectively; and s is a phosphorothioate linkage.
17. The pharmaceutical composition of claim 15 , wherein
(a) the first sense strand comprises 5′-gsgsuggaCfuUfCfUfcucaAfUfuuuaL96-3′ (SEQ ID NO:994) and the first antisense strand comprises 5′-usAfsaaaUfuGfAfgagaAfgUfccaccsasc-3′ (SEQ ID NO:1023); and
(b) the second sense strand comprises 5′-gsusguGfcAfCfUfucgcuucacaL96-3′ (SEQ ID NO:1275) and the second antisense strand comprises 5′-usGfsugaAfgCfGfaaguGfcAfcacsusu-3′ (SEQ ID NO:1285);
wherein a, g, c, and u are 2′-O-methyl (2′-OMe) A, 2′-OMe G, 2′-OMe C, and 2′-OMe U, respectively; Af, Cf, Gf, and Uf are 2′-fluoro A, 2′-fluoro C, 2′-fluoro G, and 2′-fluoro U, respectively; s is a phosphorothioate linkage; and L96 is N-[tris(GalNAc-alkyl)-amidodecanoyl)]-4-hydroxyprolinol.
18. A method of inhibiting Hepatitis B virus (HBV) gene expression and/or replication of HBV in a cell, the method comprising:
(a) contacting the cell with the double stranded RNAi agent of claim 1 ; and
(b) maintaining the cell produced in step (a) for a time sufficient to obtain degradation of the mRNA transcript of an HBV gene, thereby inhibiting expression of the HBV gene and/or replication of the HBV in the cell.
19. A method of inhibiting Hepatitis B virus (HBV) gene expression and/or replication of HBV in a cell, the method comprising:
(a) contacting the cell with the double stranded RNAi agent of claim 9 ; and
(b) maintaining the cell produced in step (a) for a time sufficient to obtain degradation of the mRNA transcript of an HBV gene, thereby inhibiting expression of the HBV gene and/or replication of the HBV in the cell.
20. A method of inhibiting Hepatitis B virus (HBV) gene expression and/or replication of HBV in a cell, the method comprising:
(a) contacting the cell with the double stranded RNAi agent of claim 11 ; and
(b) maintaining the cell produced in step (a) for a time sufficient to obtain degradation of the mRNA transcript of an HBV gene, thereby inhibiting expression of the HBV gene and/or replication of the HBV in the cell.
21. The method of claim 18 , wherein the HBV gene expression is inhibited by at least about 30%, about 40%, about 50%, about 60%, about 70%, about 80%, about 90%, about 95%, about 98%, or about 100%.
22. A method of reducing the viral load of Hepatitis B virus (HBV) in a subject infected with HBV, comprising administering to the subject a therapeutically effective amount of the double stranded RNAi agent of claim 1 , thereby reducing the viral load of HBV in the subject.
23. A method of reducing the viral load of Hepatitis B virus (HBV) in a subject infected with HBV, comprising administering to the subject a therapeutically effective amount of the double stranded RNAi agent of claim 9 , thereby reducing the viral load of HBV in the subject.
24. A method of reducing the viral load of Hepatitis B virus (HBV) in a subject infected with HBV, comprising administering to the subject a therapeutically effective amount of the double stranded RNAi agent of claim 11 , thereby reducing the viral load of HBV in the subject.
25. A method of treating a subject having a Hepatitis B virus (HBV) infection, comprising administering to the subject a therapeutically effective amount of the double stranded RNAi agent of claim 1 , thereby treating said subject.
26. The method of claim 25 , wherein the double stranded RNAi agent is administered to the subject at a weight based dose of about 0.01 mg/kg to about 10 mg/kg or about 0.5 mg/kg to about 50 mg/kg; a weight based dose of about 10 mg/kg to about 30 mg/kg; a weight based dose of about 3 mg/kg; a weight based dose of about 10 mg/kg; or a fixed dose of about 50 mg to 200 mg.
27. The method of claim 25 , wherein the double stranded RNAi agent is administered subcutaneously; or intravenously.
28. The method of claim 25 , further comprising administering to the subject an additional therapeutic agent.
29. The method of claim 28 , wherein the additional therapeutic agent is selected from the group consisting of an antiviral agent, a reverse transcriptase inhibitor, an immune stimulator, a therapeutic vaccine, a viral entry inhibitor, an oligonucleotide that inhibits the secretion or release of HbsAg, a capsid inhibitor, a covalently closed circular (ccc) HBV DNA inhibitor, and a combination of any of the foregoing.
30. A method of treating a subject having a Hepatitis B virus (HBV) infection, comprising administering to the subject a therapeutically effective amount of the double stranded RNAi agent of claim 9 , thereby treating said subject.
31. The method of claim 30 , wherein the double stranded RNAi agent is administered to the subject at a weight based dose of about 0.01 mg/kg to about 10 mg/kg or about 0.5 mg/kg to about 50 mg/kg; a weight based dose of about 10 mg/kg to about 30 mg/kg; a weight based dose of about 3 mg/kg; a weight based dose of about 10 mg/kg; or a fixed dose of about 50 mg to 200 mg.
32. The method of claim 30 , wherein the double stranded RNAi agent is administered subcutaneously; or intravenously.
33. The method of claim 30 , further comprising administering to the subject an additional therapeutic agent.
34. The method of claim 33 , wherein the additional therapeutic agent is selected from the group consisting of an antiviral agent, a reverse transcriptase inhibitor, an immune stimulator, a therapeutic vaccine, a viral entry inhibitor, an oligonucleotide that inhibits the secretion or release of HbsAg, a capsid inhibitor, a covalently closed circular (ccc) HBV DNA inhibitor, and a combination of any of the foregoing.
35. A method of treating a subject having a Hepatitis B virus (HBV) infection, comprising administering to the subject a therapeutically effective amount of the double stranded RNAi agent of claim 11 , thereby treating said subject.
36. The method of claim 35 , wherein the double stranded RNAi agent is administered to the subject at a weight based dose of about 0.01 mg/kg to about 10 mg/kg or about 0.5 mg/kg to about 50 mg/kg; a weight based dose of about 10 mg/kg to about 30 mg/kg; a weight based dose of about 3 mg/kg; a weight based dose of about 10 mg/kg; or a fixed dose of about 50 mg to 200 mg.
37. The method of claim 35 , wherein the double stranded RNAi agent is administered subcutaneously; or intravenously.
38. The method of claim 35 , further comprising administering to the subject an additional therapeutic agent.
39. The method of claim 38 , wherein the additional therapeutic agent is selected from the group consisting of an antiviral agent, a reverse transcriptase inhibitor, an immune stimulator, a therapeutic vaccine, a viral entry inhibitor, an oligonucleotide that inhibits the secretion or release of HbsAg, a capsid inhibitor, a covalently closed circular (ccc) HBV DNA inhibitor, and a combination of any of the foregoing.
40. A method of treating a subject having a Hepatitis B virus (HBV) infection, comprising administering to the subject a therapeutically effective amount of the pharmaceutical composition of claim 12 , thereby treating said subject.
41. A method of treating a subject having a Hepatitis B virus (HBV) infection, comprising administering to the subject a therapeutically effective amount of the pharmaceutical composition of claim 13 , thereby treating said subject.
42. A method of treating a subject having a Hepatitis B virus (HBV) infection, comprising administering to the subject a therapeutically effective amount of the pharmaceutical composition of claim 14 , thereby treating said subject.
43. A method of treating a subject having a Hepatitis B virus (HBV) infection, comprising administering to the subject a therapeutically effective amount of the pharmaceutical composition of claim 15 , thereby treating said subject.
44. A method of treating a subject having a Hepatitis B virus (HBV) infection, comprising administering to the subject a therapeutically effective amount of the pharmaceutical composition of claim 16 , thereby treating said subject.
45. A method of treating a subject having a Hepatitis B virus (HBV) infection, comprising administering to the subject a therapeutically effective amount of the pharmaceutical composition of claim 17 , thereby treating said subject.